AU2017258799A1 - Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cancer - Google Patents

Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cancer Download PDF

Info

Publication number
AU2017258799A1
AU2017258799A1 AU2017258799A AU2017258799A AU2017258799A1 AU 2017258799 A1 AU2017258799 A1 AU 2017258799A1 AU 2017258799 A AU2017258799 A AU 2017258799A AU 2017258799 A AU2017258799 A AU 2017258799A AU 2017258799 A1 AU2017258799 A1 AU 2017258799A1
Authority
AU
Australia
Prior art keywords
cancer
snv
nucleic acids
specific
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017258799A
Other languages
English (en)
Inventor
Aoy Tomita Mitchell
Karl Stamm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical College of Wisconsin
Original Assignee
Medical College of Wisconsin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical College of Wisconsin filed Critical Medical College of Wisconsin
Publication of AU2017258799A1 publication Critical patent/AU2017258799A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6851Quantitative amplification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/686Polymerase chain reaction [PCR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6858Allele-specific amplification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2017258799A 2016-04-29 2017-04-29 Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cancer Abandoned AU2017258799A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662330043P 2016-04-29 2016-04-29
US62/330,043 2016-04-29
PCT/US2017/030291 WO2017190104A1 (en) 2016-04-29 2017-04-29 Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cancer

Publications (1)

Publication Number Publication Date
AU2017258799A1 true AU2017258799A1 (en) 2018-12-20

Family

ID=58709564

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017258799A Abandoned AU2017258799A1 (en) 2016-04-29 2017-04-29 Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cancer

Country Status (11)

Country Link
US (1) US20200181681A1 (enExample)
EP (1) EP3449014A1 (enExample)
JP (2) JP2019518437A (enExample)
CN (1) CN109715826A (enExample)
AU (1) AU2017258799A1 (enExample)
BR (1) BR112018072195A2 (enExample)
CA (1) CA3022545A1 (enExample)
EA (1) EA201892491A1 (enExample)
IL (1) IL262640A (enExample)
MX (1) MX2018013223A (enExample)
WO (1) WO2017190104A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
BR112013020220B1 (pt) 2011-02-09 2020-03-17 Natera, Inc. Método para determinar o estado de ploidia de um cromossomo em um feto em gestação
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
US20180173846A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
US11479812B2 (en) 2015-05-11 2022-10-25 Natera, Inc. Methods and compositions for determining ploidy
RU2760913C2 (ru) 2016-04-15 2021-12-01 Натера, Инк. Способы выявления рака легкого
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
CA3042722A1 (en) * 2016-11-02 2018-05-11 The Medical College Of Wisconsin, Inc. Methods for assessing risk using mismatch amplification and statistical methods
CA3067637A1 (en) 2017-06-20 2018-12-27 The Medical College Of Wisconsin, Inc. Assessing transplant complication risk with total cell-free dna
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
US12024738B2 (en) 2018-04-14 2024-07-02 Natera, Inc. Methods for cancer detection and monitoring
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
DE69832158T2 (de) 1997-02-25 2006-08-10 Arizona Board Of Regents, Tempe Isolierung und strukturelle aufklärung der kryostatischen linearen und cyclo-depsipeptide dolastatin 16, dolastatin 17, und dolastatin 18
US20030148301A1 (en) * 1999-12-10 2003-08-07 Toshiya Aono Method of detecting nucleotide polymorphism
JP4116856B2 (ja) * 2002-10-02 2008-07-09 富士フイルム株式会社 1塩基多型の検出方法
US20130071844A1 (en) * 2010-03-24 2013-03-21 Toppan Printing Co., Ltd. Method for detecting target base sequence using competitive primer
US10077474B2 (en) * 2012-05-29 2018-09-18 Abbott Molecular, Inc. Method of designing primers, method of detecting single nucleotide polymorphisms (SNPs), method of distinguishing SNPs, and related primers, detectable oligonucleotides, and kits
US20140242582A1 (en) 2013-02-28 2014-08-28 Ariosa Diagnostics, Inc. Detection of genetic abnormalities using ligation-based detection and digital pcr
DK3194612T3 (da) * 2014-08-22 2024-10-14 Resolution Bioscience Inc Fremgangsmåder til kvantitativ genetisk analyse af cellefrit dna
HK1252152A1 (zh) * 2015-04-30 2019-05-17 Medical College Of Wisconsin, Inc. 用於評估無細胞dna的多重優化錯配擴增(moma)實時pcr

Also Published As

Publication number Publication date
US20200181681A1 (en) 2020-06-11
EP3449014A1 (en) 2019-03-06
BR112018072195A2 (pt) 2019-02-12
WO2017190104A1 (en) 2017-11-02
JP2022084647A (ja) 2022-06-07
CA3022545A1 (en) 2017-11-02
MX2018013223A (es) 2019-04-22
EA201892491A1 (ru) 2019-06-28
IL262640A (en) 2018-12-31
CN109715826A (zh) 2019-05-03
JP2019518437A (ja) 2019-07-04

Similar Documents

Publication Publication Date Title
US20200181681A1 (en) Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cancer
US20210301320A1 (en) Multiplexed optimized mismatch amplification (moma)-cancer risk assessment with non-cancer associated targets
Mastoraki et al. ESR1 methylation: a liquid biopsy–based epigenetic assay for the follow-up of patients with metastatic breast cancer receiving endocrine treatment
US11279979B2 (en) Method of determining PIK3CA mutational status in a sample
Khodakov et al. Diagnostics based on nucleic acid sequence variant profiling: PCR, hybridization, and NGS approaches
Hoshi et al. Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process
Takai et al. Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer
US20190153525A1 (en) Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing fetal well being
KR102278401B1 (ko) 빈발 돌연변이의 신속도 및 민감도 검출 방법
US20240279745A1 (en) Systems and methods for multi-analyte detection of cancer
Ball et al. Circulating tumor DNA as a marker of therapeutic response in patients with renal cell carcinoma: a pilot study
US20220356533A1 (en) Biomarker composition for diagnosing or predicting prognosis of thyroid cancer, comprising preparation capable of detecting mutation in plekhs1 gene, and use thereof
US20240093302A1 (en) Non-invasive cancer detection based on dna methylation changes
KR102416074B1 (ko) 생물학적 시료의 핵산 품질을 결정하는 방법
Sun et al. A novel xenonucleic acid-mediated molecular clamping technology for early colorectal cancer screening
Atli et al. Pros and cons for fluorescent in situ hybridization, karyotyping and next generation sequencing for diagnosis and follow-up of multiple myeloma
US20250101494A1 (en) Methods for analyzing cytosine methylation and hydroxymethylation
Chang et al. Detection of KRAS codon 12 and 13 mutations by mutant-enriched PCR assay
US12391985B2 (en) Method of determining PIK3CA mutational status in a sample
Saldivar et al. Analytic validation of NeXT Dx™, a comprehensive genomic profiling assay
EP4624573A1 (en) Probe/primer library for cancer diagnosis
Mehta et al. Robust home brew fragment sizing assay for detection of MET exon 14 skipping mutation in non–small cell lung cancer patients in resource constrained community hospitals
El-Heliebi for the Analysis of Cell-Free Circulating DNA
Prieto-Remon et al. Recent Patents in Circulating Cell-Free Tumor DNA as Biomarker in Cancer
HK1238684B (zh) 用於快速并且灵敏地检测热点突变的方法

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ MULTIPLEXED OPTIMIZED MISMATCH AMPLIFICATION (MOMA)-REAL TIME PCR FOR ASSESSING CANCER

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period